Sign up

Silverarc Capital Management, LLC

$898.5M assets · 65 holdings · Q2 2026 · Filed 13 AUG 2026

About Silverarc Capital Management, LLC’s 13F portfolio

Silverarc Capital Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Silverarc Capital Management, LLC reported $898.5M across 65 US-listed positions (). Its largest position is ASCENDIS PHARMA A/S (ASND) at 6.1% of the reported book, and its ten biggest holdings make up 45% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$898.5M
Assets (13F)
#2,543
of 8,839 by size
65
Holdings
45%
Top-10 weight
36
Buys
49
Sells
Top holdings · Q2 2026
65 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: ASND
ASCENDIS PHARMA A/S
$255.96
−5.32%
6.1%
206K$55.0M
2
NASDAQ: CELC
CELCUITY INC
$56.31
+1.28%
5.8%
501K$52.4M
3
NASDAQ: COGT
COGENT BIOSCIENCES INC
$27.74
−0.25%
5.5%
1.3M$49.6M
4
NASDAQ: URGN
UROGEN PHARMA LTD
$31.73
+6.51%
5.3%
1.3M$47.9M
5
NASDAQ: IMNM
IMMUNOME INC
$16.61
−1.01%
4.8%
2.0M$42.7M
6
NASDAQ: DNTH
DIANTHUS THERAPEUTICS INC
$84.83
+1.01%
4.2%
390K$38.0M
7
NASDAQ: RYTM
RHYTHM PHARMACEUTICALS INC
$116.80
−1.88%
3.8%
311K$34.6M
8
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
$97.57
+1.91%
3.7%
353K$33.6M
9
NASDAQ: GLUE
MONTE ROSA THERAPEUTICS INC
$8.91
−1.76%
3.0%
1.1M$26.8M
10
NASDAQ: SNDX
SYNDAX PHARMACEUTICALS INC
$9.13
+6.66%
3.0%
1.2M$26.5M
11
NASDAQ: ELVN
ENLIVEN THERAPEUTICS INC
$46.41
+3.39%
2.8%
489K$24.8M
12
NASDAQ: IMVT
IMMUNOVANT INC
$32.52
−1.96%
2.7%
619K$23.9M
13
NASDAQ: ERAS
ERASCA INC
$14.22
+3.34%
2.6%
1.3M$23.1M
14
NASDAQ: SGMT
SAGIMET BIOSCIENCES INC
$9.62
−4.85%
2.5%
2.9M$22.6M
15
NASDAQ: ABVX
ABIVAX SA
$80.65
−3.79%
2.5%
170K$22.6M
16
NASDAQ: PRAX
PRAXIS PRECISION MEDICINES I
$310.90
+1.87%
2.4%
66K$22.0M
17
NASDAQ: KOD
KODIAK SCIENCES INC
$97.90
+0.09%
2.4%
546K$21.3M
18
NASDAQ: DFTX
DEFINIUM THERAPEUTICS INC
—
—
2.1%
400K$18.8M
19
NASDAQ: VCYT
VERACYTE INC
$25.04
−2.07%
2.1%
318K$18.7M
20
NASDAQ: GH
GUARDANT HEALTH INC
$145.59
+0.31%
1.7%
100K$15.0M
21
NASDAQ: CCCC
C4 THERAPEUTICS INC
$2.44
−1.41%
1.6%
3.0M$14.2M
22
NASDAQ: ZBIO
ZENAS BIOPHARMA INC
$25.04
−5.22%
1.4%
510K$12.9M
23
NASDAQ: TRVI
TREVI THERAPEUTICS INC
$13.72
+1.55%
1.4%
678K$12.6M
24
NASDAQ: HLXC
HELIX ACQUISITION CORP III
—
—
1.4%
1.2M$12.5M
25
NASDAQ: ALXO
ALX ONCOLOGY HLDGS INC
$1.02
+5.14%
1.3%
5.7M$11.9M

Showing 1–25 of 65 positions on this page reported in this 13F.

Sector allocation
  • Healthcare94%
Recent activity · vs 2026-03-31
Bought36
  • NewASNDASCENDIS PHARMA A/S—$55.0M
  • AddedCELCCELCUITY INC+40.0%$52.4M
  • AddedIMNMIMMUNOME INC+9.0%$42.7M
  • AddedRYTMRHYTHM PHARMACEUTICALS INC+1.8%$34.6M
  • AddedORKAORUKA THERAPEUTICS INC+134%$33.6M
  • AddedSNDXSYNDAX PHARMACEUTICALS INC+36.6%$26.5M
  • NewELVNENLIVEN THERAPEUTICS INC—$24.8M
  • AddedIMVTIMMUNOVANT INC+49.5%$23.9M
  • NewSGMTSAGIMET BIOSCIENCES INC—$22.6M
  • NewDFTXDEFINIUM THERAPEUTICS INC—$18.8M
Sold49
  • ReducedCOGTCOGENT BIOSCIENCES INC−2.5%$49.6M
  • ReducedURGNUROGEN PHARMA LTD−13.4%$47.9M
  • ReducedDNTHDIANTHUS THERAPEUTICS INC−40.4%$38.0M
  • ReducedGLUEMONTE ROSA THERAPEUTICS INC−44.6%$26.8M
  • ReducedERASERASCA INC−31.8%$23.1M
  • ReducedABVXABIVAX SA−43.9%$22.6M
  • ReducedPRAXPRAXIS PRECISION MEDICINES I−8.2%$22.0M
  • ReducedKODKODIAK SCIENCES INC−44.9%$21.3M
  • ReducedZBIOZENAS BIOPHARMA INC−55.1%$12.9M
  • ReducedHLXCHELIX ACQUISITION CORP III−2.6%$12.5M
5%+ Beneficial Ownership Stakes · 2 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
RNAQ
Rainier Acquisition Corp.
13G9.7%854KFiled 13 NOV 2026
2
HLXC
Helix Acquisition Corp. III
13G6.8%1.2MFiled 13 MAY 2026

Showing all 2 disclosed stakes.

Reading Silverarc Capital Management, LLC’s 13F portfolio

Silverarc Capital Management, LLC’s $898.5M 13F book is spread across 65 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 45%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are ASND, CELC, COGT, URGN and IMNM, led by ASCENDIS PHARMA A/S (ASND) at 6.1% of the portfolio. The heaviest sector exposure is Healthcare (94%).

What Silverarc Capital Management, LLC changed last quarter

Between 2026-03-31 and Q2 2026, Silverarc Capital Management, LLC was a net seller: it opened 20 new positions and added to 16 more, while trimming 27 and closing 22 outright. Against a 65-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ASCENDIS PHARMA A/S (ASND), and its biggest reduction was COGENT BIOSCIENCES INC (COGT).

What a 13F does and doesn’t reveal

A 13F captures only Silverarc Capital Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Silverarc Capital Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Silverarc Capital Management, LLC's profile on this page is built directly from those filings.

How current is the 13F data on Silverarc Capital Management, LLC's page?

It reflects Silverarc Capital Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Silverarc Capital Management, LLC files its next quarterly report, this page refreshes automatically.

Can I see Silverarc Capital Management, LLC's complete list of holdings?

This page highlights Silverarc Capital Management, LLC's largest positions rather than all 65 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Silverarc Capital Management, LLC's filings.

Does a 13F show everything Silverarc Capital Management, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Silverarc Capital Management, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Silverarc Capital Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.